Gout Market Research Report – Forecast to 2027

Gout Market Research Report: By Type (Tophaceous Gout and Pseudogout), By Treatment (Medication, Self-Care), By Diagnosis (Ct Scan, Ultrasound, Urine Test, Blood Test), And By End-User (Hospitals, Specialty Centers, Homecare) – Global Forecast Till 2027

ID: MRFR/Pharma/4453-HCR | | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Gout is a common form of inflammatory arthritis. Gout is caused due to higher levels of uric acid in the blood. Major risk factors that are likely to cause gout are certain health factors such as high cholesterol, high blood pressure, and certain medications that can cause high levels of uric acid. Additionally, factors such as diet containing red meat, obesity, and high consumption of alcohol can cause gout.


The global gout market is majorly driven by the increasing prevalence of obesity, rising older population leading to rise in the patient population, the rise in cigarette smoking population, and growing mass young population inclined towards a sedentary lifestyle. Additionally, factors such as government initiatives and support, rising demand for advanced treatment, and growing market players offering newer products are likely to drive the market.


According to the United Nations, in 2017 approximately over 962 million population was aged over 60 and above globally. The United Nations has also estimated that by 2050, the number of older population is likely to reach 425 million. This increasing aging population is likely to propel the growth of the global gout market. Factors that are likely to hamper the growth of the market are the lack of awareness about the symptoms of the disease.


Global gout market is expected to grow at a CAGR of 8.4% during the forecast period.


Figure: Global Gout Market, by Region, 2016 (%)


 Gout Market, by Region


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis


Intended Audience



  • Pharmaceutical Manufacturers and Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Segments 


The global gout market is segmented on the basis of treatment, type, end-user, and diagnosis. 


On the basis of type, the market is segmented into tophaceous gout and pseudogout.


On the basis of treatment, the market is segmented into medications and self-care. The medication segment is further sub-segmented into Allopurinol, Febuxostat, Probenecid, Indomethacin, Diclofenac, and Ibuprofen.


On the basis of diagnosis, the market is segmented into X-ray, CT scan, blood test, MRI, ultrasound, urine test, and others.


On the basis of end-user, the market is segmented into hospitals, specialty centers, and homecare.


Research Methodology


 Gout Market,Methodology


Source: World Health Organization, Centers for Disease Control and Prevention, Expert Interview, Annual Report, White Paper, Company Presentation, and Market Research Future Analysis


Regional Analysis


The North American gout market is a growing market. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. The increasing number of passive smokers, along with the increasing older population is likely to drive the market. Additionally, the growing healthcare expenditure and increasing demand for technologically advanced treatments and products along with the increasing government support are likely to enhance the growth of the gout market in North America. Additionally, according to a survey conducted by the National Centre for Health Statistics, in the year 2014, around 70% of adults were considered to be obese in the U.S.


Europe is the second largest market and holds a healthy share in the global gout market. The European market is expected to register a healthy CAGR during the forecast period owing to the availability of newer and advanced treatment facilities and increasing skilled medical professionals along with growing need for better healthcare infrastructure. Furthermore, increasing older population, along with the growing inclination towards sedentary lifestyle are driving the growth of the gout market. For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above. This increasing older population is likely to drive the growth of the gout market.


Asia Pacific is expected to be the fastest growing market due to increasing prevalence of chronic gout. China is the fastest growing region owing to an increasingly older population. The increasing awareness about the health and availability of new treatment methods drives the market in this region. The increasing healthcare expenditure and improvement in the standard of living are driving the growth of the gout market in the Asia Pacific region.


The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the development of the healthcare industry and increasing availability of specialty care centers.


Key Players                                                                                                         


Some of the key players in the gout market are Takeda Pharmaceutical Company Ltd., Savient Pharmaceuticals, AstraZeneca plc, Merck& Co. Inc., Inc.Ardelyx, Inc., Astellas Pharma Inc., and Novartis AG.



Frequently Asked Questions (FAQ) :


Gout Market CAGR would be 8.4% during the forecast period.

Diagnosis segments in Gout Market report are CT scan, X-ray, MRI, ultrasound, blood test, urine test, and others.

End users mentioned in Gout Market report are specialty centers, hospitals, and homecare.

North America would lead Gout Market growth.

The Asia Pacific market would register the fastest Gout Market growth.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Gout Market, by Type

6.1 Introduction

6.2 Tophaceous Gout

6.2.1 Market Estimates & Forecast, 2020–2027

6.3 Pseudogout

6.3.1 Market Estimates & Forecast, 2020–2027

7. Global Gout Market, by Diagnosis

7.1 Introduction

7.2 X-ray

7.2.1 Market Estimates & Forecast, 2020–2027

7.3 Blood Test

7.3.1 Market Estimates & Forecast, 2020–2027

7.4 MRI

7.4.1 Market Estimates & Forecast, 2020–2027

7.5 CT Scan

7.5.1 Market Estimates & Forecast, 2020–2027

7.6 Urine Test

7.6.1 Market Estimates & Forecast, 2020–2027

7.7 Ultrasound

7.7.1 Market Estimates & Forecast, 2020–2027

7.8 Others

7.8.1 Market Estimates & Forecast, 2020–2027

8. Global Gout Market, by Treatment

8.1 Introduction

8.2 Medications

8.2.1 Allopurinol

8.2.2 Febuxostat

8.2.3 Probenecid

8.2.4 Indomethacin

8.2.5 Diclofenac

8.2.6 Ibuprofen

8.2.7 Market Estimates & Forecast, 2020–2027

8.3 Self Care

8.3.1 Market Estimates & Forecast, 2020–2027

9. Global Gout Market, by End-User

9.1 Introduction

9.2 Hospitals

9.2.1 Market Estimates & Forecast, 2020–2027

9.3 Specialty Centers

9.3.1 Market Estimates & Forecast, 2020–2027

9.4 Home Care

9.4.1 Market Estimates & Forecast, 2020–2027

10 Global Gout Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 U.K.

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 Takeda Pharmaceutical Company Ltd.

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Novartis AG

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Savient Pharmaceuticals

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 AstraZeneca Plc

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 GlaxoSmithKline plc

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Merck& Co. Inc.

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Teijin Pharma Ltd.

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of the Pharmaceutical Industry

14 Appendix

LIST OF TABLES

Table 1 Gout Industry Synopsis, 2020–2027

Table 2 Global Gout Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Gout Market, by Region, 2020–2027, (USD Million)

Table 5 Global Gout Market, by Treatment, 2020–2027, (USD Million)

Table 6 Global Gout Market, by Diagnosis, 2020–2027, (USD Million)

Table 7 Global Gout Market, by End-User, 2020–2027, (USD Million)

Table 8 North America Gout Market, by Treatment, 2020–2027, (USD Million)

Table 9 North America Gout Market, by Diagnosis, 2020–2027, (USD Million)

Table 10 North America Gout Market, by End-User, 2020–2027, (USD Million)

Table 11 U.S. Gout Market, by Treatment, 2020–2027, (USD Million)

Table 12 U.S. Gout Market, by Diagnosis, 2020–2027, (USD Million)

Table 13 U.S. Gout Market, by End-User, 2020–2027, (USD Million)

Table 14 Canada Gout Market, by Treatment, 2020–2027, (USD Million)

Table 15 Canada Gout Market, by Diagnosis, 2020–2027, (USD Million)

Table 16 Canada Gout Market, by End-User, 2020–2027, (USD Million)

Table 17 South America Gout Market, by Treatment, 2020–2027, (USD Million)

Table 18 South America Gout Market, by Diagnosis, 2020–2027, (USD Million)

Table 19 South America Gout Market, by End-User, 2020–2027, (USD Million)

Table 20 Europe Gout Market, by Treatment, 2020–2027, (USD Million)

Table 21 Europe Gout Market, by Diagnosis, 2020–2027, (USD Million)

Table 22 Europe Gout Market, by End-User, 2020–2027, (USD Million)

Table 23 Western Europe Gout Market, by Treatment, 2020–2027, (USD Million)

Table 24 Western Europe Gout Market, by diagnosis, 2020–2027, (USD Million)

Table 25 Western Europe Gout Market, by End-User, 2020–2027, (USD Million)

Table 26 Eastern Europe Gout Market, by Treatment, 2020–2027, (USD Million)

Table 27 Eastern Europe Gout Market, by diagnosis, 2020–2027, (USD Million)

Table 28 Eastern Europe Gout Market, by End-User, 2020–2027, (USD Million)

Table 29 Asia Pacific Gout Market, by Treatment, 2020–2027, (USD Million)

Table 30 Asia Pacific Gout Market, by diagnosis, 2020–2027, (USD Million)

Table 31 Asia Pacific Gout Market, by End-User, 2020–2027, (USD Million)

Table 32 Middle East & Africa Gout Market, by Treatment, 2020–2027, (USD Million)

Table 33 Middle East & Africa Gout Market, by diagnoses, 2020–2027, (USD Million)

Table 34 Middle East & Africa Gout Market, by End-User, 2020–2027, (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Gout Market

Figure 3 Segmentation Market Dynamics for the Gout Market

Figure 4 Global Gout Market Share, by Treatment 2020

Figure 5 Global Gout Market Share, by Diagnosis 2020

Figure 6 Global Gout Market Share, by End-User, 2020

Figure 7 Global Gout Market Share, by Region, 2020

Figure 8 North America Gout Market Share, by Country, 2020

Figure 9 Europe Gout Market Share, by Country, 2020

Figure 10 Asia Pacific Gout Market Share, by Country, 2020

Figure 11 Middle East & Africa Gout Market Share, by Country, 2020

Figure 12 Global Gout Market: Company Share Analysis, 2020 (%)

Figure 13 Teijin Pharma Ltd.: Key Financials

Figure 14 Teijin Pharma Ltd: Segmental Revenue

Figure 16 Teijin Pharma Ltd: Geographical Revenue

Figure 17 AstraZeneca Plc. Key Financials

Figure 18 AstraZeneca plc: Segmental Revenue

Figure 19 AstraZeneca plc: Geographical Revenue

Figure 20 GlaxoSmithKline Plc. Key Financials

Figure 21 GlaxoSmithKline plc: Segmental Revenue

Figure 22 GlaxoSmithKline Plc. Geographical Revenue

Figure 23 Novartis AG: Key Financials

Figure 24 Novartis AG: Segmental Revenue

Figure 25 Novartis AG: Geographical Revenue

Figure 26 GlaxoSmithKline plc: Key Financials

Figure 27 GlaxoSmithKline plc: Segmental Revenue

Figure 28 GlaxoSmithKline Plc. Geographical Revenue

Figure 29 Ardelyx, Inc.: Key Financials

Figure 30 Ardelyx, Inc.: Segmental Revenue

Figure 31 Ardelyx, Inc.: Geographical Revenue

Figure 32 Astellas Pharma Inc.: Key Financials

Figure 33 Astellas Pharma Inc.: Segmental Revenue

Figure 34 Astellas Pharma Inc.: Geographical Revenue